Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)
Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)
Recruiting · NCT03202303 · Registry updated 2025-10-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD) | autism, autism spectrum disorder, neurodevelopmental disorder, pervasive developmental disorder, psychiatric disorder | Recruiting | Phase 2 | 2025-10-22 | NCT03202303 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| GW Pharmaceuticals Ltd | 1 |
| Jazz Pharmaceuticals | 60 |
| Montefiore Medical Center | 93 |
| United States Department of Defense | 319 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Montefiore Medical Center | The Bronx | United States | 198 |
| New York University (NYU) Langone | New York | United States | 1 |